NGM

Verisk Pioneers New Approach to Catastrophe Risk with Release of Next Generation Models

Retrieved on: 
Monday, April 8, 2024
Uncertainty, VRSK, Risk, Society, NGM, Policy, Touchstone, Insurance, Risk assessment, File, P&C, Language, Risk management

This launch marks the first successful effort by a catastrophe modeling firm to bring its full suite of models to a next generation modeling framework.

Key Points: 
  • This launch marks the first successful effort by a catastrophe modeling firm to bring its full suite of models to a next generation modeling framework.
  • NGM offers a deeper understanding of uncertainty and a more comprehensive and sophisticated solution for natural catastrophe risk management.
  • The next generation financial module in NGM delivers an accurate and reliable global view of risk across the insurance industry.
  • The use of catastrophe models is important for decision-making in the dynamic risk landscape of today’s insurance market.

NGM Bio Announces Closing of Tender Offer

Retrieved on: 
Friday, April 5, 2024
Atlas, Patient, SAN, NGM, Column, Sub, Expiration, Guggenheim Partners, Therapy, Mergers and acquisitions, TCG, Holding company

The tender offer and related withdrawal rights expired at one minute after 11:59 p.m. Eastern Time on April 4, 2024 (the “Expiration Date”).

Key Points: 
  • The tender offer and related withdrawal rights expired at one minute after 11:59 p.m. Eastern Time on April 4, 2024 (the “Expiration Date”).
  • As of the Expiration Date, a total of 22,323,295 shares of NGM Bio common stock were validly tendered, and not validly withdrawn, representing approximately 27% of the outstanding shares of NGM Bio common stock as of the Expiration Date.
  • As of the Expiration Date, the number of shares validly tendered in accordance with the terms of the tender offer and not validly withdrawn satisfied the minimum tender condition, and all other conditions to the tender offer were satisfied or waived.
  • Following the closing of the tender offer, Merger Sub merged with and into NGM Bio and all shares of NGM Bio common stock that had not been validly tendered (other than shares held by stockholders who properly demanded appraisal of such shares or shares held by affiliates of TCG and certain other stockholders who agreed to exchange their shares for shares of Parent) were converted into the right to receive the Offer Price (the “Merger”).

Kuehn Law Encourages NGM, CTLT, SDPI, and HRT Investors to Contact Law Firm

Retrieved on: 
Friday, March 22, 2024
Catalent, PLLC, Human, General Atlantic, NGM, Column, HireRight, Advertising, Superior, Security (finance)

NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.

Key Points: 
  • NEW YORK, March 22, 2024 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers.
  • Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies.
  • Concerned shareholders are encouraged to contact Justin Kuehn, Esq., at [email protected] or call (833) 672-0814.
  • Kuehn Law covers all case costs and does not charge its investor clients.

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates HRT, NGM

Retrieved on: 
Thursday, March 21, 2024
HireRight, NGM, Column, Sale, Fraud, Advertising, General Atlantic, LP, Security (finance)

NGM Biopharmaceuticals, Inc. (NASDAQ: NGM)’s sale to affiliates of The Column Group, LP for $1.55 in cash per share.

Key Points: 
  • NGM Biopharmaceuticals, Inc. (NASDAQ: NGM)’s sale to affiliates of The Column Group, LP for $1.55 in cash per share.
  • If you are a NGM shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual Meeting

Retrieved on: 
Tuesday, March 19, 2024
Patient, SAN, NGM, Pembrolizumab, Abstract, AACR, Therapy

SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, CA.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that two abstracts highlighting clinical data from the ongoing Phase 1/2 clinical trial of NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, have been selected for presentation at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, CA.
  • Title: NGM707 in combination with pembrolizumab in advanced or metastatic solid tumors: Preliminary results from dose escalation
    This presentation will provide more detailed findings from the Phase 1 Part 1b dose escalation cohort of the ongoing Phase 1/2 trial evaluating NGM707 in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, for the treatment of patients with advanced or metastatic solid tumors than as originally reported by NGM Bio in January 2024.
  • Title: Pharmacodynamic and predictive biomarker results from the phase I dose escalation study of NGM707, an ILT2/ILT4 dual antagonist antibody, in patients with advanced solid tumors

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates HRT, NGM, SCTL

Retrieved on: 
Saturday, March 16, 2024
CDMO, HireRight, NGM, Column, Sale, Fraud, Advertising, General Atlantic, Society, LP, Security (finance)

If you are a HireRight shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a HireRight shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

NGM BIOPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of NGM Biopharmaceuticals, Inc. - NGM

Retrieved on: 
Wednesday, March 13, 2024
Professional Services, Health, Legal, Class Action Lawsuit, Pharmaceutical, Biotechnology, KSF, NGM, Column, Sale, LP

and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of NGM Biopharmaceuticals, Inc. (NasdaqGS: NGM) to affiliates of The Column Group, LP.

Key Points: 
  • and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of NGM Biopharmaceuticals, Inc. (NasdaqGS: NGM) to affiliates of The Column Group, LP.
  • Under the terms of the proposed transaction, shareholders of NGM will receive $1.55 in cash for each share of NGM that they own.
  • Please note that the merger is structured as a tender offer, such that time may be of the essence.
  • To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com .

NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Monday, March 11, 2024
Research, GDF15, PSC, Part, Vomiting, Pregnancy, MSS, Liver, Atlas, Preterm birth, NGM, LAIR1, Nausea, Hospital, ILT3, GFRAL, Food and Drug Administration, NASH, Therapy, Woman, Toxicology, Liver disease, CRC, Cirrhosis, Biomarker, Place of birth, Colorectal cancer, Agreement, Acquisition, Plan, FGF19, AASLD, FDA, Food, Weight loss, Primary sclerosing cholangitis, Pembrolizumab, Dehydration, Bile, Hyperemesis gravidarum, HG, Patient, Pre-eclampsia, Malnutrition, Pharmaceutical industry

--On February 26, 2024, announced that it had entered into the Agreement and Plan of Merger with Atlas Neon Parent, Inc., and Atlas Neon Merger Sub, Inc.--

Key Points: 
  • The combination of NGM707 and pembrolizumab was generally well-tolerated at all four doses (200, 600, 1200, 1800 mg) of NGM707.
  • Additional details can be found in NGM Bio’s recent filings with the United States Securities and Exchange Commission (SEC).
  • NGM Bio anticipates that the Offer and the Merger contemplated under the Merger Agreement will be consummated in the second quarter of 2024.
  • If the Merger is effected, NGM Bio’s common stock will be delisted from The Nasdaq Stock Market LLC and NGM Bio will be privately held.

INVESTIGATION UPDATE: Halper Sadeh LLC Investigates CHRD, AA, NGM, SCTL

Retrieved on: 
Saturday, March 9, 2024
NGM, Enerplus, LP, Alumina Limited, Society, Fraud, Sale, Advertising, CDMO, Column, Security (finance)

If you are a Chord shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are a Chord shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.

SHAREHOLDER UPDATE: Halper Sadeh LLC Investigates AA, NGM, KNTE

Retrieved on: 
Saturday, March 2, 2024
NGM, LP, Alumina Limited, Fraud, Sale, Advertising, Column, Security (finance)

If you are an Alcoa shareholder, click here to learn more about your rights and options .

Key Points: 
  • If you are an Alcoa shareholder, click here to learn more about your rights and options .
  • Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits on behalf of shareholders.
  • Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email [email protected] or [email protected] .
  • Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct.